NewsVIEW ALL
-
Stroke in China: advances and challenges in epidemiology, prevention, and management
With over 2 million new cases annually, stroke is associated with the highest disability-adjusted life-years lost of any disease in China. The burden is expected to increase further as a result of population ageing, an ongoing high prevalence of risk factors (eg, hypertension), and inadequate management. Despite improved access to overall health services, the […]
-
Glucose control after stroke
Intensive intravenous glucose control did not improve functional outcome compared with standard insulin control in patients with stroke who have hyperglycaemia— and it may even increase the risk of hypoglycaemia. In the SHINE trial, presented in the International Stroke Conference 2019 by Karen Johnston (University of Virginia, Charlottesville, VA, USA), 581 patients were randomised to […]
-
Intensive Blood Pressure lowering after thrombolysing Ischaemic Stroke Patients
Intensive blood pressure lowering in patients treated with alteplase for acute ischaemic stroke did not lead to a significant improvement in outcome compared with guideline based blood pressure lowering. In the ENCHANTED study, presented by Craig Anderson (George Institute for Global Health, Sydney, Australia in the International stroke conference 2019) and Thompson Robinson (University of […]
-
Acute dual antiplatelet therapy for minor ischaemic stroke or transient ischaemic attack
Yongjun Wang and colleagues discuss recent evidence for using dual antiplatelet therapy to reduce recurrence of stroke or transient ischaemic attack In summary, DAPT should be started as soon as possible within 24 hours of minor ischaemic stroke or high risk transient ischaemic attack and should be continued up to 21 days. The 21st day is the […]
